Description
What is the use of nusinersen?
- Targets the backup gene: People with SMA lack a working SMN1 gene. They have a backup gene called SMN2 that makes too little of a vital protein called SMN.
- Boosts protein production: Nusinersen is an antisense oligonucleotide (a type of genetic therapy) that helps the SMN2 gene produce a full, working protein to protect motor neurons.
Has Spinraza (nusinersen) been launched in India?
Patient Access Facilitation for Spinraza (nusinersen)
To give request – contact sourcing facilitation team
Company Name: Lucknow Speciality pharma
References:
- FDA Approves High Dose Regimen of SPINRAZA® for Spinal Muscular Atrophy, Reflecting Progress Made Possible Through Decades of MDA Supported Research
- MHRA authorises Biogen’s higher-dose Spinraza for SMA treatment
- Search Orphan Drug Designations and Approvals
- FDA Approves SPINRAZA (Nusinersen) for the Treatment of Spinal Muscular Atrophy in Pediatric and Adult Patients





